Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S6W-44088 · Session 6

What dosage is specified in the national clinical pathway for responsiveness testing with the drug sapropterin in individuals with phenylke…

Answered Asked by Jamie Greene LD Lodged 5 Mar 2026

The question

To ask the Scottish Government what dosage is specified in the national clinical pathway for responsiveness testing with the drug sapropterin in individuals with phenylketonuria (PKU) in Scotland, and whether that pathway aligns with the recommendations of the British Inherited Metabolic Disease Group (BIMDG).

The answer

Answered by Jenni Minto on 11 Mar 2026 · 6 days after it was lodged, on time

In Scotland, the national clinical pathway for sapropterin use in individuals with phenylketonuria (PKU) applies the UK best-practice consensus guidelines developed by the British Inherited Metabolic Disease Group (BIMDG). This ensures a consistent approach to dosing and assessment of treatment response across the UK’s metabolic services.The pathway specifies a starting dose of 10 mg per kilogram of body weight per day for the period of responsiveness testing.The decision to prescribe a medicine, and which medicine to prescribe, is entirely for the clinician in charge of a person’s care, having taken into account their clinical condition, safety and any relevant clinical guidance.

In the Official Report

No contribution in the Official Report cites S6W-44088 by reference.